Processing and characterization of high environmental efficiency composites based on PLA and hazelnut shell flour (HSF) with biobased plasticizers derived from epoxidized linseed oil (ELO)

[EN] Different amounts of epoxidized linseed oil (ELO) have been added to poly(lactic acid)-PLA composites with hazelnut shell flour (HSF) to provide a plasticizing effect and improve the low intrinsic ductile properties of PLA/HSF composites. Mechanical, thermal, thermo-mechanical and dynamic mechanical properties have been studied in terms of the weight percentage ELO. Mechanical resistant properties in both tensile and flexural tests decrease with wt.% ELO while a remarkable increase with wt.% ELO is obtained. These results reveal a clear plasticization effect of ELO but, in addition, internal structure of PLA/HSF/ELO composites shows good PLA-HSF (matrix-particle) interactions so that indicating that ELO also provides a coupling effect between PLA matrix and HSF filler. ELO addition leads to a decrease in storage modulus (G ) obtained by dynamic mechanical thermal analysis (DMTA) in torsion mode thus giving clear evidence of the plasticization effect of ELO. Overall, the use of ELO in PLA/HSF composites is an attracting way to improve the low intrinsic fragility of these green composites; furthermore, ELO provides an improvement on thermal stability and a coupling effect between the polymer matrix and the surrounding lignocellulosic filler.This research was supported by the Ministry of Economy and Competitiveness - MINECO, Grant Number: MAT2014-59242-C2-1-R. Authors also thank to "Conselleria d'Educacio, Cultura i Esport" - Generalitat Valenciana, Grant Number: GV/2014/008 for financial support.Balart Gimeno, JF.; Fombuena Borrás, V.; Fenollar Gimeno, OÁ.; Boronat Vitoria, T.; Sánchez Nacher, L. (2016). Processing and characterization of high environmental efficiency composites based on PLA and hazelnut shell flour (HSF) with biobased plasticizers derived from epoxidized linseed oil (ELO). Composites Part B: Engineering. 86:168-177. https://doi.org/10.1016/j.compositesb.2015.09.063S1681778

Is there a role for chemotherapy in prostate cancer?

There is evidence from randomised-controlled trials that patients with symptomatic hormone-refractory prostate cancer may experience palliative benefit from chemotherapy with mitoxantrone and prednisone. This treatment is well tolerated, even by elderly patients, although the cumulative dose of mitoxantrone is limited by cardiotoxicity. Treatment with docetaxel or paclitaxel, with or without estramustine, appears to convey higher rates of prostate-specific antigen response in phase II trials, but is more toxic. Large phase III trials comparing docetaxel with mitoxantrone have completed accrual. There is no role for chemotherapy in earlier stages of disease except in the context of a well-designed clinical trial

Hardness, Decay and Water Resistance of Polypropylene/Montmorillonite/Almond Shell Flour Composites

The effect of montmorillonite (MMT) loading (0, 2.5, and 5 wt%) and almond shell flour (ASF) content (30, 35, and 40 wt%) on the decay resistance, hardness, water resistance of injection molded polypropylene (PP) composites was investigated. The amount of maleic anhydride grafted polypropylene was kept constant at 2% for all formulations. White-rot (Trametes versicolor) fungal treatment was applied to the produced composites for 14 weeks according to BS 838:1961 with the Petri dishes method. The weight loss of the composites decreased with increasing MMT content. The highest hardness (66 Shore D) was noted in the undecayed control composites (40ASF60PP0MMT) while the lowest hardness (61.3 Shore D) was recorded in the decayed control composites (30ASF70PP0MMT). The water absorption of the undecayed and decayed composites decreased with increasing amount montmorillonite at 30-40 wt% content of the ASF loading level. The water absorption of the decayed composites was higher than that of the undecayed composites but their thickness swelling was lower. Based on the findings obtained from the present study, a 35/5/65/2 formulation of the ASF/MMT/PP/MAPP can be used in outdoor applications requiring a high dimensional stability

Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Purpose: Cyclin D/CDK4/6 is critical in controlling the G1 to S checkpoint. CCND, the gene encoding cyclin D, is known to be amplified in a variety of solid tumors. Palbociclib is an oral CDK4/6 inhibitor, approved in advanced breast cancer in combination with endocrine therapy. We explored the efficacy of palbociclib in patients with nonbreast solid tumors containing an amplification in CCND1, 2, or 3. Patients and methods: Patients with tumors containing a CCND1, 2, or 3 amplification and expression of the retinoblastoma protein were assigned to subprotocol Z1B and received palbociclib 125 mg once daily for 21 days of a 28-day cycle. Tumor response was assessed every two cycles. Results: Forty patients were assigned to subprotocol Z1B; 4 patients had outside assays identifying the CCND1, 2, or 3 amplification and were not confirmed centrally; 3 were ineligible and 2 were not treated (1 untreated patient was also ineligible), leaving 32 evaluable patients for this analysis. There were no partial responses; 12 patients (37.5%) had stable disease as best response. There were seven deaths on study, all during cycle 1 and attributable to disease progression. Median progression-free survival was 1.8 months. The most common toxicities were leukopenia (n = 21, 55%) and neutropenia (n = 19, 50%); neutropenia was the most common grade 3/4 event (n = 12, 32%). Conclusions: Palbociclib was not effective at treating nonbreast solid tumors with a CCND1, 2, or 3 amplification in this cohort. These data do not support further investigation of single-agent palbociclib in tumors with CCND1, 2, or 3 amplification

Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma

Chimeric antigen receptor (CAR) therapy is a promising immunotherapeutic strategy for treating multiple refractory blood cancers, but further advances are required for solid tumor CAR therapy. One challenge is identifying a safe and effective tumor antigen. Here, we devise a strategy for targeting hepatocellular carcinoma (HCC, one of the deadliest malignancies). We report that T and NK cells transduced with a CAR that recognizes the surface marker, CD147, also known as Basigin, can effectively kill various malignant HCC cell lines in vitro, and HCC tumors in xenograft and patient-derived xenograft mouse models. To minimize any on-target/off-tumor toxicity, we use logic-gated (log) GPC3–synNotch-inducible CD147-CAR to target HCC. LogCD147-CAR selectively kills dual antigen (GPC3+CD147+), but not single antigen (GPC3-CD147+) positive HCC cells and does not cause severe on-target/off-tumor toxicity in a human CD147 transgenic mouse model. In conclusion, these findings support the therapeutic potential of CD147-CAR-modified immune cells for HCC patients